Microbot Medical Inc. (MBOT) Income Statement
MBOT 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsMBOT revenue and net income
MBOT growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
MBOT quarterly EPS vs estimates
Microbot Medical beat the analyst EPS estimate in 4 of the last 8 quarters. Next report: November 11, 2026 (estimate $-0.08).
MBOT income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $47,000 | $91,000 | $106,000 | $102,000 | $76,000 | $68,000 | $84,000 | $54,000 | $21,000 | $10,000 |
| Gross profit | −$47,000 | −$91,000 | −$106,000 | −$102,000 | −$76,000 | −$68,000 | −$84,000 | −$54,000 | −$21,000 | −$10,000 |
| Research & development | $6.3M | $6.6M | $5.7M | $7.7M | $6.2M | $3.4M | $3.0M | $2.9M | $1.3M | $1.1M |
| Sales, general & admin | $8.2M | $5.0M | $4.1M | $5.8M | $5.4M | $5.7M | $4.2M | $4.7M | $4.1M | $8.7M |
| Total operating expenses | $14.7M | $11.5M | $9.7M | $13.3M | $11.4M | $9.1M | $7.2M | $7.2M | $5.3M | $9.6M |
| Operating income | −$14.7M | −$11.6M | −$9.9M | −$13.3M | −$11.4M | −$9.1M | −$7.2M | −$7.2M | −$5.3M | −$9.6M |
| Interest income | — | — | $212,000 | $54,000 | — | — | $103,000 | $16,000 | $43,000 | $27,000 |
| Interest expense | — | — | — | $131.3M | $44,000 | $80,000 | $103,000 | $0 | $238,000 | $334,000 |
| Income before taxes | −$13.1M | −$11.4M | −$10.7M | −$13.2M | −$11.3M | −$9.2M | −$7.2M | −$7.3M | −$7.6M | −$9.7M |
| Income taxes | — | $182,000 | — | −$118.0M | −$44,000 | $80,000 | $103,000 | $20,000 | $2.3M | $28,000 |
| Net income | −$13.1M | −$11.4M | −$10.7M | −$13.2M | −$11.3M | −$9.2M | −$7.2M | −$7.3M | −$7.6M | −$9.7M |
| EBITDA | −$13.1M | −$11.4M | −$10.6M | −$13.3M | −$11.2M | −$9.0M | −$7.1M | −$7.2M | −$5.2M | −$9.6M |
| EPS (diluted) | −$0.29 | −$0.74 | −$1.08 | −$1.81 | −$1.59 | −$1.29 | −$1.61 | −$2.35 | −$184.77 | −$4.44 |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $241,000 | $105,000 | $0 | $0 | $0 | $0 | $84,000 | $0 | $0 | $0 | $142,000 | $0 |
| Cost of revenue | $884,000 | $103,000 | $10,000 | $10,000 | $12,000 | $15,000 | $26,000 | $23,000 | $14,000 | $28,000 | $35,000 | $20,000 |
| Gross profit | −$643,000 | $2,000 | −$10,000 | −$10,000 | −$12,000 | −$15,000 | −$26,000 | −$23,000 | −$14,000 | −$28,000 | −$35,000 | −$20,000 |
| Research & development | $1.9M | $1.3M | $1.5M | $1.2M | $2.1M | $1.5M | $2.0M | $2.1M | $1.4M | $1.1M | $1.1M | $1.6M |
| Sales, general & admin | — | $3.0M | $2.4M | $2.7M | $1.6M | $1.6M | $1.4M | $1.2M | $1.1M | $1.2M | $938,000 | $932,000 |
| Total operating expenses | $5.5M | $4.3M | $4.1M | $3.9M | $3.7M | $3.0M | $3.4M | $3.3M | $2.5M | $2.4M | $2.0M | $2.5M |
| Operating income | −$6.2M | −$4.3M | −$4.1M | −$3.9M | −$3.7M | −$3.0M | −$3.4M | −$3.3M | −$2.5M | −$2.4M | −$2.1M | −$2.5M |
| Interest income | — | $649,000 | — | — | $223,000 | $104,000 | — | — | $46,000 | $13,000 | — | $98,000 |
| Interest expense | — | — | — | — | — | — | — | — | — | — | $66,000 | — |
| Income before taxes | −$5.6M | −$3.7M | −$3.5M | −$3.6M | −$3.5M | −$2.6M | −$3.4M | −$3.2M | −$2.5M | −$2.4M | −$3.2M | −$2.4M |
| Income taxes | — | — | — | — | — | — | — | — | — | −$15,276 | $66,000 | $59,586 |
| Net income | −$5.6M | −$3.7M | −$3.5M | −$3.6M | −$3.5M | −$2.6M | −$3.4M | −$3.2M | −$2.5M | −$2.4M | −$3.2M | −$2.4M |
| EBITDA | −$5.6M | −$3.7M | −$3.5M | −$3.6M | −$3.5M | −$2.6M | −$3.4M | −$3.2M | −$2.5M | −$2.3M | −$3.1M | −$2.4M |
| EPS (diluted) | −$0.08 | −$0.05 | −$0.04 | −$0.07 | −$0.10 | −$0.08 | −$0.20 | −$0.20 | −$0.17 | −$0.17 | −$0.26 | −$0.21 |
| Gross margin | −266.8% | 1.9% | — | — | — | — | −31.0% | — | — | — | −24.6% | — |
| Operating margin | −2,567.6% | −4,114.3% | — | — | — | — | −4,083.3% | — | — | — | −1,456.3% | — |
| Net margin | −2,334.9% | −3,496.2% | — | — | — | — | −4,038.1% | — | — | — | −2,221.1% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in MBOT's financial statements (latest annual report filed March 26, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
MBOT financial results
Microbot Medical reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $13.1 million. Diluted earnings per share came to −$0.29.
See the MBOT stock overview for the latest quote and news, or the MBOT chart for price history and technical indicators.
MBOT income statement FAQ
Does Microbot Medical have revenue?
Microbot Medical reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Microbot Medical profitable?
No. Microbot Medical reported a net loss of $13.1 million in fiscal 2025.
How much does Microbot Medical spend on research and development?
Microbot Medical spent $6.3 million on research and development in fiscal 2025.
What are Microbot Medical's earnings per share?
Microbot Medical earned $-0.29 per diluted share in fiscal 2025, compared with $-0.74 a year earlier.
When will Microbot Medical report its next earnings?
Microbot Medical is expected to report results for the quarter ending September 30, 2026 on November 11, 2026.
When does Microbot Medical's fiscal year end?
Microbot Medical's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 26, 2026.